Literature DB >> 29620443

MiR-2861 Behaves as a Biomarker of Lung Cancer Stem Cells and Regulates the HDAC5-ERK System Genes.

Mengya Zhao1,2, Lin Li1, Jundong Zhou3, Xueyuan Cui1,2, Qingmei Tian1,4, Yaqing Jin1,5, Yimin Zhu1.   

Abstract

Cancer stem cells (CSCs) are responsible for cancer initiating, recurrence, and drug resistance. Discovery of novel biomarkers for CSCs is helpful for early diagnosis and prognosis. Lung cancer stem cells (LCSCs) were closely related to the occurrence and development of lung cancer. In our study, the important role of miR-2861 in maintaining the stemness of LCSCs was investigated. The LCSC differentiation model was established through introducing serum into the medium of H460 spheres. miR-2861 expression was significantly higher in LCSCs no matter compared to the differentiation cells or normal cells. HDAC5 expression was positively correlated with miR-2861 in LCSCs, and knockdown of miR-2861 decreased the expression of HDAC5, which implied that HDAC5 may be involved in the differentiation of LCSCs mediated by miR-2861. The role of HDAC5 in the regulation of LCSC differentiation was further verified by the inhibitory effect of LMK-235 on the phosphorylation of ERK1/2, which was recognized as the regulator of CSC differentiation. Our study provided a better understanding of miR-2861 and HDAC5 axis in maintaining the stemness of LCSCs and laid a foundation for molecular targeted therapy.

Entities:  

Keywords:  HDAC5; differentiation; lung cancer stem cells; miR-2861

Mesh:

Substances:

Year:  2018        PMID: 29620443     DOI: 10.1089/cell.2017.0045

Source DB:  PubMed          Journal:  Cell Reprogram        ISSN: 2152-4971            Impact factor:   1.987


  11 in total

Review 1.  Processing body (P-body) and its mediators in cancer.

Authors:  Bernard Nsengimana; Faiz Ali Khan; Ebenezeri Erasto Ngowi; Xuefeng Zhou; Yu Jin; Yuting Jia; Wenqiang Wei; Shaoping Ji
Journal:  Mol Cell Biochem       Date:  2022-01-28       Impact factor: 3.396

Review 2.  Differential molecular mechanistic behavior of HDACs in cancer progression.

Authors:  Tashvinder Singh; Prabhsimran Kaur; Paramdeep Singh; Sandeep Singh; Anjana Munshi
Journal:  Med Oncol       Date:  2022-08-16       Impact factor: 3.738

3.  Precision Oncology: Artificial Intelligence and DNA Methylation Analysis of Circulating Cell-Free DNA for Lung Cancer Detection.

Authors:  Ray Bahado-Singh; Kyriacos T Vlachos; Buket Aydas; Juozas Gordevicius; Uppala Radhakrishna; Sangeetha Vishweswaraiah
Journal:  Front Oncol       Date:  2022-05-04       Impact factor: 5.738

4.  Pharmacological Inhibition of Class IIA HDACs by LMK-235 in Pancreatic Neuroendocrine Tumor Cells.

Authors:  Julia Wanek; Martin Gaisberger; Marlena Beyreis; Christian Mayr; Katharina Helm; Florian Primavesi; Tarkan Jäger; Pietro Di Fazio; Martin Jakab; Andrej Wagner; Daniel Neureiter; Tobias Kiesslich
Journal:  Int J Mol Sci       Date:  2018-10-12       Impact factor: 5.923

5.  A `one-two punch' therapy strategy to target chemoresistance in estrogen receptor positive breast cancer.

Authors:  Feng Chi; Jiayi Liu; Samuel W Brady; Patrick A Cosgrove; Aritro Nath; Jasmine A McQuerry; Sumana Majumdar; Philip J Moos; Jeffrey T Chang; Michael Kahn; Andrea H Bild
Journal:  Transl Oncol       Date:  2020-11-19       Impact factor: 4.243

6.  Fentanyl Inhibits Lung Cancer Viability and Invasion via Upregulation of miR-331-3p and Repression of HDAC5.

Authors:  Shengkai Gong; Liang Ying; Yu'ning Fan; Zhentao Sun
Journal:  Onco Targets Ther       Date:  2020-12-23       Impact factor: 4.147

7.  Relationship between the miRNA Profiles and Oncogene Mutations in Non-Smoker Lung Cancer. Relevance for Lung Cancer Personalized Screenings and Treatments.

Authors:  Alberto Izzotti; Gabriela Coronel Vargas; Alessandra Pulliero; Simona Coco; Irene Vanni; Cristina Colarossi; Giuseppina Blanco; Antonella Agodi; Martina Barchitta; Andrea Maugeri; Gea Oliveri Conti; Margherita Ferrante; Salvatore Sciacca
Journal:  J Pers Med       Date:  2021-03-05

Review 8.  Insights Into the Function and Clinical Application of HDAC5 in Cancer Management.

Authors:  Jun Yang; Chaoju Gong; Qinjian Ke; Zejun Fang; Xiaowen Chen; Ming Ye; Xi Xu
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

Review 9.  Therapeutic Opportunities of Targeting Histone Deacetylase Isoforms to Eradicate Cancer Stem Cells.

Authors:  Peng-Chan Lin; Hao-Yu Hsieh; Po-Chen Chu; Ching S Chen
Journal:  Int J Mol Sci       Date:  2018-07-02       Impact factor: 5.923

10.  Assessment by miRNA microarray of an autologous cancer antigen-pulsed adoptive immune ensemble cell therapy (AC-ACT) approach; demonstrated induction of anti-oncogenic and anti-PD-L1 miRNAs.

Authors:  Masanobu Chinami; Kaoru Iwabuchi; Yoshiteru Muto; Yasuhiko Uchida; Ryu Arita; Rana A Shuraim; Chaker N Adra
Journal:  Clin Case Rep       Date:  2019-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.